Enterome develops off‑the‑shelf peptide immunotherapies that use bacterial peptides mimicking tumor antigens to activate pre‑existing CD8⁺ effector memory T cells. The OncoMimics™ platform selects high‑affinity, non‑self peptides from a gut‑microbiome database and delivers them as stable, room‑temperature subcutaneous injections, which can be combined with standard oncology agents. Phase 2 data across multiple cancer types show rapid, durable responses with a benign safety profile.
Funding
$19M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
IFFounders
Product
Problem
Patients with various cancers often experience limited treatment options because existing immunotherapies rely on targeting self‑antigens, leading to immune tolerance and modest efficacy. Additionally, many effective immunotherapies require individualized manufacturing, restricting access and scalability.
Solution
Enterome delivers off‑the‑shelf peptide immunotherapies through its OncoMimics™ platform, which exploits bacterial peptides that mimic tumor‑associated antigens to activate pre‑existing effector memory T cells. By selecting high‑affinity, non‑self peptides from a curated gut‑microbiome database, the approach generates rapid, durable CD8⁺ T‑cell responses while bypassing self‑tolerance mechanisms. The resulting multi‑peptide formulations are administered as subcutaneous injections and can be combined with standard of care agents such as rituximab or checkpoint inhibitors. Clinical data from Phase 2 trials in follicular lymphoma, glioblastoma, adrenal tumors, and colorectal cancer demonstrate meaningful response rates and a benign safety profile, supporting a scalable, off‑the‑shelf cancer immunotherapy solution.
Target Audience
Oncologists and hematologists treating indolent B‑cell malignancies, glioblastoma, adrenal cortical carcinoma, and metastatic colorectal cancer, as well as pharmaceutical partners seeking off‑the‑shelf immunotherapy candidates.
Features
- Proprietary Mimicry biocomputational pipeline that screens >20 million gut‑microbiome proteins to identify bacterial peptides with <10 nM affinity for tumor antigens.
- Multi‑peptide composition targeting several lineage‑specific markers or TAAs in each product to reduce tumor heterogeneity and antigen‑escape risk.
- Synthetic peptide manufacturing that yields a stable, room‑temperature formulation suitable for subcutaneous injection and global distribution.
- Induction of rapid expansion of patient‑resident memory CD8⁺ T cells, providing fast and sustained anti‑tumor immunity.
- Demonstrated safety and immunogenicity in >230 patients across multiple indications, with Phase 2 objective response rates up to 100% in combination settings.
- Compatibility with standard therapies (e.g., rituximab, nivolumab, bevacizumab) enabling combination regimens.
- De‑risked chemistry, manufacturing, and control (CMC) pathway and regulatory strategy for accelerated approvals.